SIGA Technologies, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by SIGA Technologies, Inc. on January 14, 2003, reporting events occurring on December 31, 2002. The company is a Delaware corporation engaged in the development of technologies, with principal executive offices in New York, New York.
Key Financial Metrics
The filing details a private placement of common stock completed on December 31, 2002.
- Initial Gross Proceeds: $990,000 from the sale of 900,000 shares.
- Initial Net Proceeds: $891,000.
- Anticipated Additional Gross Proceeds: Up to $860,000 total from remaining shares (627,300 shares for $690,000 and 172,700 shares for $170,000).
- Anticipated Additional Net Proceeds: Up to $774,000 total from remaining shares.
- Pro Forma Cash Position: As of November 30, 2002, cash and cash equivalents were $1,542,182. Adjusted for the initial net proceeds, the pro forma cash balance is $2,433,182.
- Pro Forma Total Assets: Increased from $2,275,165 to $3,166,165.
The filing does not provide specific revenue, profit, or operating margin figures for the period, as the focus is on the capital raise transaction.
Material Changes
The primary material change is the increase in liquidity and equity capital resulting from the private placement. The pro forma balance sheet reflects an increase in cash and additional paid-in capital of $891,000. The filing notes a net loss for the two months ended November 30, 2002, but does not quantify the specific loss amount in the text provided.
Outlook, Risks, and Contingencies
Forward-Looking Statements: The company includes standard disclaimers regarding forward-looking statements concerning future performance, product efficacy, and clinical trials. Actual results may differ materially from expectations.
Risks: Key risks identified include the failure of potential products to demonstrate efficacy or safety in pre-clinical or clinical trials and the risk of not obtaining necessary governmental approvals.
Contingencies: The receipt of the additional $170,000 in gross proceeds (172,700 shares) is contingent upon the completion of the placement, with no assurance given that this closing will occur.
Investor Verification Checklist
- Verify the final closing status of the remaining 172,700 shares and the associated $170,000 gross proceeds.
- Review the Form 10-K for the fiscal year ended December 31, 2001, for detailed historical financial performance and risk factors.
- Confirm the specific amount of the net loss for the two months ended November 30, 2002, referenced in the pro forma statement description.
- Monitor subsequent filings for updates on clinical trial results and regulatory approval status.